Introduction
============

Psoriasis is a common inflammatory skin disease that affects 2--4% of the world population.^[@bib1]^ Patients with psoriasis present with erythematous, scaly patches and plaques that can affect any part of their body.^[@bib2]^ The impact of psoriasis on patients\' quality of life is similar to that for patients living with insulin-dependent diabetes, depression and angina.^[@bib3]^

Increasing epidemiological evidence suggests that patients with psoriasis may be more obese compared with the general population. Although the exact mechanism underlying the epidemiological association between psoriasis and obesity is uncertain, researchers have theorized that adipocyte elaboration of pro-inflammatory cytokines may exacerbate psoriasis.^[@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ Understanding the epidemiological relationship between psoriasis and obesity is also important for delineating risk factors for other comorbid diseases that may result from obesity. For example, obesity is a risk factor for cardiovascular diseases, type II diabetes mellitus, obstructive sleep apnea and osteoarthritis.^[@bib8]^ Better understanding the strength of the relationship between psoriasis and obesity will therefore help ensure that future observational studies include adequate adjustment for the presence of comorbid obesity among patients with psoriasis.

In this systematic review and meta-analysis of observational studies, we synthesized the current literature on the association between psoriasis and obesity based on epidemiological studies from around the world.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib24]^

Materials and methods
=====================

We searched MEDLINE, EMBASE and Cochrane Central Register using the following search criteria: 'Psoriasis\' \[Mesh\] AND (('Obesity\'\[Mesh\]) OR ('Body Mass Index\'\[Mesh\])). Our search was limited to English language, human subject studies published from 1 January 1980 to 1 January 2012. Furthermore, we manually searched the reference sections of retrieved articles for any additional studies that were not included in the initial search. To be eligible for inclusion in the systematic review, the original studies needed to fulfill the following criteria: case--control, cross-sectional, cohort or nested case--control design; evaluation of obesity in conjunction with psoriasis; and analyses that compared psoriasis patients with control groups. Specifically, the studies must have evaluated the prevalence or incidence of obesity as defined by physical examination, patient self-report, medical chart review or medical billing codes. Whenever body mass index (BMI) was available, we included studies that defined obesity as a BMI⩾30 kg m^−2^.

A total of 130 articles were retrieved from the initial search, and 8 additional studies were found from review of the reference sections ([Figure 1](#fig1){ref-type="fig"}). After manually reviewing all abstracts, 77 full-text articles were further examined. In all, 15 of these studies were excluded because they were reviews; 1 was a duplicate study; 5 assessed only psoriatic arthritis patients; 7 did not include a non-psoriasis control group; 8 were letters, commentaries or editorials without original data; and 25 did not report measures of association between psoriasis and obesity. After these exclusions, 16 publications were included in the meta-analysis. For the purposes of meta-analysis, one publication^[@bib18]^ was treated as two studies, because two separate control populations were used in that publication.

Two reviewers (CTH and AWA) independently extracted the data and performed the systematic review, and any disagreements were adjudicated by consensus. The Meta-Analysis of Observational Studies in Epidemiology guidelines were used to guide analysis.^[@bib25]^ For each study included, we recorded the study year, country in which the study population lived, setting in which the study took place, study design, numbers of case and control subjects, age, gender, whether the results were adjusted for comorbidities, data collection processes (prospective or retrospective), whether the results were a primary or secondary analysis of the publication and whether psoriasis disease severity was assessed. To measure study quality, we used a previously validated six-point scale, with values of 0 or 1 assigned to study design, assessment of exposure, assessment of outcome, control for confounding, evidence of bias and assessment of psoriasis severity.^[@bib26]^ Studies with a score of 0--3 were categorized as lower quality, whereas studies with scores of 4--6 were categorized as higher quality.^[@bib26]^

The majority of studies were case--control in design and reported adjusted odds ratios (ORs). Studies that reported prevalence (*n*=15) were analyzed using meta-analysis, whereas the one study that reported incidence^[@bib15]^ was summarized. To estimate the pooled OR, we initially used both fixed-effects and random-effects models of DerSimonian and Laird.^[@bib27]^ For each study of prevalence, the crude ORs were identified based on the publication. In cases where multivariate adjustment was reported, the effect size and reported upper and lower bounds of the 95% confidence interval (CI) were log-transformed. The inverse variance method was then used to calculate the pooled OR. Study heterogeneity was assessed using the *I*^2^ statistic. Owing to significant study heterogeneity, reported pooled ORs are based on random-effects modeling.

Publication bias was assessed using visual inspection of a funnel plot of the study size vs s.e., with formal statistical testing using the Begg adjusted rank correlation test.^[@bib28],\ [@bib29]^ To explore sources of study heterogeneity, we performed meta-regression using prespecified variables and random-effects meta-analysis. Prespecified sources of heterogeneity included study country, subject location (ambulatory or inpatient), multivariate adjustment for confounders, prospective vs retrospective study design, ascertainment of prevalence vs incidence, primary vs secondary analysis, ascertainment of psoriasis disease severity, measure of outcome and study quality (0--3 vs 4--6). All analyses were performed using STATA Version 11.2 (STATA Corp., College Station, TX, USA). No funding sources supported this work. All authors have read and agree to the manuscript as written.

Results
=======

We identified 16 observational studies with a total of 2.1 million study participants fulfilling our inclusion criteria. Among them, 201 831 patients had psoriasis ([Table 1](#tbl1){ref-type="table"}). Fifteen of these studies reported prevalence among patients with psoriasis, whereas only one study^[@bib15]^ assessed the incidence of obesity among patients with preexisting psoriasis. Obesity was defined in most studies as a BMI⩾30, but a few studies used only medical diagnostic codes for obesity. Many of these studies assessed obesity as a secondary outcome in conjunction with prevalence of metabolic syndrome, but most studies adjusted for obesity independently.

All studies reported measures of association between psoriasis and obesity; the studies that found a statistically significant association after controlling for other covariates reported adjusted ORs ranging from 1.03 to 1.9 ([Table 2](#tbl2){ref-type="table"}). Meta-analysis revealed significant between-study heterogeneity (*I*^2^=98%). Using random-effects meta-analysis to account for between-study heterogeneity, the pooled OR for obesity among patients with psoriasis was 1.66 (95% CI 1.46--1.89, [Figure 2](#fig2){ref-type="fig"}).

Visual inspection of a funnel plot revealed possible publication bias, but formal testing with the Egger test did not reveal any definite publication bias (*P*=0.1). Meta-regression was also performed using prespecified variables to assess possible sources of study heterogeneity ([Table 3](#tbl3){ref-type="table"}). Studies that performed multivariate adjustment reported a significantly lower strength of association between psoriasis and prevalence of obesity (OR 1.41, 95% CI 1.26--1.58 for studies with adjusted OR vs OR 2.32, 95% CI 1.79--3.01 for studies with unadjusted OR, *P*=0.004 for comparison).

Four studies reported the relative association of mild psoriasis with obesity ([Figure 3](#fig3){ref-type="fig"}).^[@bib9],\ [@bib16],\ [@bib18],\ [@bib23]^ The pooled OR for obesity among patients with mild psoriasis was 1.46 (95% CI 1.17--1.82). Five studies reported the relative association of moderate-to-severe psoriasis with obesity ([Figure 4](#fig4){ref-type="fig"}), with a pooled OR of 2.23 (95% CI 1.63--3.05).^[@bib9],\ [@bib13],\ [@bib16],\ [@bib18],\ [@bib23]^

Although obesity likely predates the diagnosis of psoriasis in most cases, one study examined obesity incidence over time among patients with psoriasis. This study was conducted using the General Practice Research Database, a UK-based cohort of patients treated in general medical practices. Among a cohort of 44 164 patients with psoriasis, 2760 patients (6.3%) had a new diagnosis of obesity during follow-up. When compared with a matched cohort without psoriasis, those with psoriasis had a hazard ratio of 1.18 (95% CI 1.14--1.23)^[@bib15]^ for new-onset obesity.

Discussion
==========

This systematic review and meta-analysis showed that the current literature supports an association between psoriasis and obesity. Specifically, compared with the general population, psoriasis patients are at significantly increased odds of obesity. Our meta-analysis of the cross-sectional and case--control studies showed that psoriasis patients have \>50% increased odds of being obese compared with the general population. Where psoriasis severity data were available, the pooled OR for those with moderate-to-severe psoriasis was also significantly higher than that for patients with mild psoriasis.

Although the precise mechanism underlying the association between psoriasis and obesity is unknown, several lines of basic and translational research suggest that adipocytes and inflammatory-type macrophages may contribute to both disease processes. Adipose tissue is an active endocrine organ that has a key role in lipid and glucose metabolism, inflammation and coagulation, and insulin-mediated processes.^[@bib30],\ [@bib31]^ Macrophages are the key immune cell type that perpetuates inflammation within adipose tissue. Activated macrophages in adipose tissue stimulate adipocytes to secrete inflammatory mediators that establish and maintain an inflammatory state in obesity. Adipose tissue, especially visceral adipose tissue, then secretes bioactive products collectively known as adipocytokines or adipokines. The co-existence of psoriasis and obesity is at least in part attributed to the function of adipokines and their downstream effects.

The role of the various adipokines in psoriasis is an area of active investigation. For example, leptin is an adipokine that serves as an afferent signal of the nutritional and fat mass status to the hypothalamus and thereby regulates appetite and body weight.^[@bib32]^ Hyperleptinemia has been associated with increased intima-media thickness of the common carotid artery and with arterial thrombosis.^[@bib33],\ [@bib34]^ Studies in psoriasis have shown that leptin levels are elevated in psoriasis patients^[@bib6],\ [@bib35],\ [@bib36],\ [@bib37]^ compared with healthy controls, and psoriasis is an independent risk factor for hyperleptinemia.^[@bib35]^ Although an increase in pro-inflammatory adipokines is seen in psoriasis, a decrease in regulatory adipokines is also observed in psoriasis. For example, an inverse relationship exists between obesity and adiponectin, a cytokine that has an anti-inflammatory and regulatory role in atherosclerosis.^[@bib38]^ In psoriasis, the adiponectin level was decreased in psoriasis patients compared with healthy controls.^[@bib4]^ Furthermore, adiponectin level in psoriasis patients was inversely correlated with psoriasis severity and tumor necrosis factor-α levels.^[@bib36]^

Although obesity likely predates or co-exists with psoriasis, one study examined new-onset obesity in patients with existing psoriasis.^[@bib15]^ The authors found a slightly increased risk for developing obesity in psoriasis patients compared with controls. It is possible that some psoriasis patients are reluctant to engage in physical activities where their skin disease may be visible to others. Thus, in addition to genetic and immune-mediated mechanisms, behavioral factors may have an additional role in explaining the association between psoriasis and obesity. Although a few studies suggest that the use of tumor necrosis factor antagonists may be associated with weight gain in psoriasis patients,^[@bib39],\ [@bib40],\ [@bib41],\ [@bib42],\ [@bib43]^ larger studies are necessary to elucidate the effect of systemic medications on obesity. This is one potential rationale for the stronger association between obesity and severe psoriasis. Alternative explanations might include a more active systemic inflammatory disease leading to greater alterations in adipocyte function, dysregulated metabolism and concomitant development of obesity and severe psoriasis.

This systematic review and meta-analysis must be interpreted in the context of the available primary studies. The methods for identifying psoriasis and obesity differed among the studies; while some studies used diagnostic codes to identify obesity, others used BMI measurements. Psoriasis severity was assessed in a minority of studies. The variations in the study findings were likely attributable to the differences in study design, patient population, and ascertainment of predictors and outcomes. Despite the potential heterogeneity among the studies, the directionality of the association between psoriasis and obesity is nearly uniform among the studies, and the overall finding from the meta-analysis is strongly supportive of the association between psoriasis and obesity.

In summary, this systematic review and meta-analysis revealed that psoriasis patients have \>50% odds for obesity compared with those without psoriasis. Patients with more severe psoriasis are at higher odds of obesity compared with those with mild psoriasis. In patients with preexisting psoriasis, their likelihood of developing new-onset obesity is higher than those without psoriasis. Clinical recommendations to reduce weight in obese patients with psoriasis may have beneficial effects in both obesity-associated comorbidities and possibly their psoriasis severity. Future studies are necessary to elucidate the mechanisms underlying the association between obesity and psoriasis and to determine the impact of systemic medications used for psoriasis indications on modifying obesity.
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###### Study population characteristics: psoriasis and obesity

  *Study*                                                   *Study setting*                                                *Study design*                                                         *Total number of patients*                                    *Mean age*                                                      
  --------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------ -------------------------------
  [a](#t1-fn2){ref-type="fn"}Naldi *et al.*^[@bib17]^       Italy; outpatient (dermatology departments)                    Retrospective case--control                                                       690                                                    560                                 Median age of 36               Median age of 38
  [a](#t1-fn2){ref-type="fn"}Herron *et al.*^[@bib14]^      USA; outpatient (dermatology clinics)                          Prospective cross-sectional                                                       4080                                                   557                                       45.7                           49.8
  [a](#t1-fn2){ref-type="fn"}Neimann *et al.*^[@bib18]^     UK; outpatient (GPRD)                                          Prospective case--control                                 Mild Ps: 465 252 Severe Ps: 14 065 Combined: 479 317   Mild Ps: 127 706 Severe Ps: 3 854 Combined: 131 560   Mild Ps:45.7 Severe Ps: 46.3   Mild Ps: 46.4 Severe Ps: 49.8
  Cohen *et al.*^[@bib11]^                                  Israel; outpatient (CHS database)                              Retrospective case--control                                                       6643                                                   340                                        47                            47.7
  [a](#t1-fn2){ref-type="fn"}Kaye *et al.*^[@bib15]^        UK; outpatient (GPRD)                                          Prospective nested case--control: incidence of obesity                          219 784                                                44 164                                  Not reported                   Not reported
  Cohen *et al.*^[@bib12]^                                  Israel; outpatient (CHS database)                              Retrospective case--control                                                      48 677                                                16 850                                       51                            42.7
  Xiao *et al.*^[@bib23]^                                   China; outpatient (medical records)                            Retrospective cross-sectional                                                     1521                                                  3092                                       43.6               Mild Ps: 43.6 Severe Ps: 46.3
  [a](#t1-fn2){ref-type="fn"}Driessen *et al.*^[@bib13]^    Netherlands; outpatient (clinic database)                      Retrospective cross-sectional                                                     396                                                    107                                       51.2                           48.5
  Takahashi *et al.*^[@bib21]^                              Japan; outpatient (dermatology clinic)                         Retrospective case--control                                                       154                                                    151                                       57.2                           53.1
  [a](#t1-fn2){ref-type="fn"}Schmitt *et al.*^[@bib19]^     Germany; outpatient (GKV-database Saxony)                      Retrospective case--control                                                       3147                                                  3147                                       57.1                           57.1
  [a](#t1-fn2){ref-type="fn"}Augustin *et al.*^[@bib10]^    Germany; outpatient (health insurance database)                Retrospective cross-sectional                                                  1 310 090                                               33 981                                  Not reported                   Not reported
  [a](#t1-fn2){ref-type="fn"}Al-Mutairi *et al.*^[@bib9]^   Kuwait; outpatient (medical records)                           Retrospective case--control                                                       1835                                                  1835                                       52.7                           52.3
  [a](#t1-fn2){ref-type="fn"}Warnecke *et al.*^[@bib22]^    Germany; inpatients and outpatients (dermatology department)   Retrospective case--control                                                       100                                                    100                                       51.9                           51.8
  [a](#t1-fn2){ref-type="fn"}Zhang *et al.*^[@bib24]^       China; outpatient (dermatology clinic)                         Retrospective cross-sectional                                                     1166                                                  4452                                       36.7                           36.5
  [a](#t1-fn2){ref-type="fn"}Shapiro *et al.*^[@bib20]^     Israel; inpatient (dermatology department)                     Retrospective case--control                                                       1079                                                  1079                                       68.7                           68.6
  Langan *et al.*^[@bib16]^                                 UK; outpatient (THIN database)                                 Retrospective case--control                                                      40 650                                                 4065                                   Not reported                   Not reported

Abbreviation: CHS, Clalit Health Services; GPRD, General Practice Research Database; THIN, The Health Improvement Network.

Denotes that obesity was the primary study outcome.

###### Study outcomes: psoriasis and obesity

  *Study*                           *Study period*   *Outcome ascertainment*                *Obesity in control patients (BMI in kg m*^*−2*^)                   *Obesity in psoriasis patients (BMI in kg m*^*−2*^)               *Measure of association (95% CI)*
  --------------------------------- ---------------- -------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  ^a^Naldi *et al.*^[@bib17]^       1988--1997       Interview/clinical examination         BMI⩾30: *n*=57 (8.3%)                                               BMI⩾30: *n*=71 (12.9%)                                            BMI⩾30: AOR 1.9 (1.2--2.8)
  ^a^Herron *et al.*^[@bib14]^      Not reported     Questionnaire                          Mean BMI of 26.2 (s.d. 5.1) Median BMI of 25.7                      Mean BMI of 29.1 (s.d. 7.3) Median BMI of 27.8                    OR 2.39 (1.98--2.90)
  ^a^Neimann *et al.*^[@bib18]^     1987--2002       OXMIS/Read                             BMI\>30: Mild Ps: *n*=36 117 (13.1%) Severe Ps: *n*=1 093 (13.0%)   BMI\>30: Mild Ps: *n*=13 404 (15.8%) Severe Ps: *n*=545 (20.7%)   BMI\>30: Mild Ps: OR 1.29 (1.26--1.32) Mild Ps: AOR 1.27 (1.24--1.31) Severe Ps: OR 1.84 (1.60--2.11) Severe Ps: AOR 1.79 (1.55--2.05)
  Cohen *et al.*^[@bib11]^          Not reported     Diagnosis in database                  Obesity: *n*=1 561 (23.5%)                                          Obesity: *n*=100 (29.4%)                                          OR 1.4 (1.1--1.7) AOR 1.3 (1.0--1.7)
  ^a^Kaye *et al.*^[@bib15]^        1991--2005       OXMIS/Read                             BMI⩾30: *n*=11 996 (5.5%)                                           BMI⩾30: *n*=2 760 (6.3%)                                          BMI⩾30: HR 1.18 (1.14--1.23)
  Cohen *et al.*^[@bib12]^          Not reported     Diagnosis of obesity in database       Obesity: *n*=1 768 (3.6%)                                           Obesity: *n*=1 419 (8.4%)                                         OR 2.4 (2.3--2.6) AOR 1.7 (1.5--1.9)
  Xiao *et al.*^[@bib23]^           1999--2007       Medical code consistent with obesity   Obesity: *n*=183 (12.03)                                            Obesity: Mild Ps: *n*=227 (14.02%) Severe Ps: *n*=296 (20.10%)    Mild Ps: OR 1.41 (1.08--1.85) Mild Ps: AOR 1.42 (1.06--1.91) Severe Ps: OR 1.51 (1.15--1.98) Severe Ps: AOR 1.52 (1.13--2.04)
  ^a^Driessen *et al.*^[@bib13]^    Not reported     Manual chart review; BMI⩾30            Mean BMI of 24.9 (s.d. not reported)                                Mean BMI of 28.5 (s.d. not reported)                              BMI⩾30: OR 5.49 (3.09--9.74)
  Takahashi *et al.*^[@bib21]^      2006--2008       Manual chart review                    Obesity: *n*=36 (22.7%)                                             Obesity: *n*=60 (39.7%)                                           OR 2.24 (1.36--3.69)
  ^a^Schmitt *et al.*^[@bib19]^     2003--2004       ICD-10                                 Obesity: *n*=329 (10.5%)                                            Obesity: *n*=490 (15.6%)                                          OR 1.58 (1.36--1.83) AOR 1.63 (1.39--1.90)
  ^a^Augustin *et al.*^[@bib10]^    2005             ICD-10                                 Obesity: *n*=136 118 (10.4%)                                        Obesity: *n*=6 055 (17.8%)                                        PR 1.72 (1.68--1.76)
  ^a^Al-Mutairi *et al.*^[@bib9]^   2003--2007       Manual chart review                    BMI\>30: *n*=195 (17%)                                              BMI\>30: Mild Ps: *n*=372 (32.5%) Severe Ps: *n*=49 (41%)         BMI\>30: Mild Ps: OR 2.36 (1.93--2.87) Severe Ps: OR 3.42 (2.30--5.10)
  ^a^Warnecke *et al.*^[@bib22]^    2009--2010       Questionnaire/clinical assessment      BMI\>30: *n*=33 (33%) Mean BMI of 27.7 (s.d. 5.6)                   BMI\>30: *n*=44 (44%) Mean BMI of 30.1 (s.d. 7.7)                 AOR 1.03 (0.97--1.09)
  ^a^Zhang *et al.*^[@bib24]^       1997--2009       Clinical assessment                    BMI⩾30: *n*=30 (2.6%); Mean BMI of 22.86 (s.d. 3.37)                BMI⩾30: *n*=179 (4.0%); Mean BMI of 23.29 (s.d. 3.25)             BMI⩾30: OR 1.68 (1.13--2.49)
  ^a^Shapiro *et al.*^[@bib20]^     1993--2006       ICD-9                                  Obesity: *n*=94 (8.7%)                                              Obesity: *n*=143 (13.3%)                                          OR 1.60 (1.22--2.11) AOR 1.32 (0.99--1.76)
  Langan *et al.*^[@bib16]^         Not reported     Read codes (THIN database)             BMI 30--35: *n*=7 678 (20.5%) BM*I*\>35: *n*=4 907 (13.1%)          BMI 30--35: *n*=887 (23.5%) BM*I*\>35: *n*=662 (17.5%)            BMI\>30: OR 1.38 (1.29--1.48) AOR 1.25 (1.16--1.34)

Abbreviations: AOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; HR, hazard ratio; ICD, International Classification of Disease; OXMIS, Read, Oxford Medical Information System and Read diagnostic codes; PR: prevalence ratio; THIN, The Health Improvement Network database.

Denotes that obesity was the primary study outcome.

###### Potential prespecified sources of heterogeneity explored among the studies reporting an association between psoriasis and obesity

  *Prespecified source of heterogeneity*   *Number of estimates*   *Stratified fixed-effects meta-analysis OR (95% CI)*   *Meta-regression* P*-value for heterogeneity*
  ---------------------------------------- ----------------------- ------------------------------------------------------ -----------------------------------------------
  *Study location*                                                                                                        0.78
   USA                                     1                       2.39 (1.98--2.90)                                       
   Europe                                  8                       1.56 (1.31--1.86)                                       
   Other                                   7                       1.69 (1.39--2.06)                                       
                                                                                                                           
  *Source population*                                                                                                     0.09
   Inpatient                               2                       1.12 (0.89--1.41)                                       
   Outpatient                              14                      1.75 (1.54--1.99)                                       
                                                                                                                           
  *Statistical adjustment*                                                                                                0.004
   Not adjusted                            6                       2.32 (1.79--3.01)                                       
   Adjusted                                10                      1.41 (1.26--1.58)                                       
                                                                                                                           
  *Study quality*                                                                                                         0.13
   Lower (0--3)                            6                       2.19 (1.70--2.81)                                       
   Higher (4--6)                           11                      1.48 (1.30--1.68)                                       
                                                                                                                           
  *Outcome ascertainment*                                                                                                 0.86
   Billing data                            1                       1.72 (1.68--1.76)                                       
   Chart review                            11                      1.66 (1.44--1.91)                                       
   Examination                             4                       1.66 (0.97--2.83)                                       
                                                                                                                           
  *Analysis of outcome*                                                                                                   0.42
   Primary                                 11                      1.75 (1.49--2.06)                                       
   Secondary                               5                       1.48 (1.24--1.77)                                       
                                                                                                                           
  *Severity of psoriasis*                                                                                                 0.55
   No distinction                          10                      1.62 (1.32--1.97)                                       
   Mild vs severe                          6                       1.74 (1.43--2.12)                                       

Abbreviations: CI, confidence interval; OR, odds ratio.
